

Supplementary Table 1. Baseline characteristics of biopsy-confirmed LN patients based on the 2019 EULAR/ACR criteria (n=126)

Characteristics	SLE (n=120)	non-SLE (n=6)	Nominal P value
Age, mean \pm SD	35.5 \pm 13.0	34 \pm 15.8	
Sex, male/female	20/100	1/5	
Disease duration, months	1.0 (0.5, 4.0)	1.0 (0.5, 120.0)	0.578
SLEDAI	18.48 \pm 5.43	18.0 \pm 2.76	
ANA titer			
< 1:40	0	1	
1:40	0	5	<0.0001
\geq 1:80	120	0	
Clinical manifestation			
Renal domain	Positive (%)	Positive (%)	
Protein >0.5 g/24 hours	121 (100%)	6(100%)	1.000
Class II or V lupus nephritis	33	1	
Class III or IV lupus nephritis	87 (72.73%)	5(83.33%)	
Constitutional			
Fever	27 (22.31%)	2(33.33%)	0.619
Mucocutaneous			
Acute cutaneous lupus	36 (29.75%)	2(33.33%)	1.000
Subacute cutaneous lupus or discoid rash	3 (2.48%)	1(16.67%)	0.178
Non-scarring alopecia	16 (13.22%)	1(16.67%)	0.586
Oral ulcer	8 (6.61%)	1(16.67%)	0.363
Musculoskeletal domain			
joint involvement	5 (4.13%)	0	1.000
Serosal domain			
Pleural or pericardial effusion	35 (28.93%)	1(16.67%)	0.674
Acute pericarditis	0	0	1.000
Neuropsychiatric domain			
Delirium	0	0	1.000
Psychosis	0	0	1.000
Seizure	3 (2.48%)	0	1.000
Haematologic domain			
Leucopenia	66 (55.37%)	2(33.33%)	
Thrombocytopenia	32 (27.27%)	2(33.33%)	
Autoimmune haemolysis	8 (6.61%)	1(16.67%)	0.363
Laboratory criteria			
Immunologic domain			
Anti- β 2GP1 antibodies (IgG and/or IgM)	32 (26.45%)	0	0.336

Anticardiolipin antibodies (IgG and/or IgM)	32 (26.45%)	0	0.336
Lupus anticoagulant*	0	0	
Complement domain			
C3	105 (87.60%)	6(100%)	1.000
C4	94 (78.51%)	5(83.33%)	1.000
Highly specific antibodies domain	89	2	0.019
Anti-dsDNA antibody	68 (56.20%)	1(16.67%)	0.090
Anti-Sm antibody	41 (34.71%)	1(16.67%)	0.663
ACR/EULAR criteria score	25.05 ± 0.60	21 ± 5.44	0.098
Treatment response			
renal CR	77 (64.17%)	5 (83.33%)	
renal PR	33 (27.50%)	1 (16.67%)	0.585
no remission	10 (8.33%)	0	
Long-term outcome			
flare	14 (11.67%)	0	1.0
ERSD	2 (1.67%)	0	1.0
death	3 (2.5%)	0	1.0

*The data of lupus anticoagulant was absent.

EULAR: European League Against Rheumatism; ACR: American College of Rheumatology; Anti-dsDNA, antibodies to double-stranded DNA; Anti-Sm, anti-Smith; LN, lupus nephritis; C3/4, complement 3/4.